Your session is about to expire
← Back to Search
Nivolumab Combinations for Liver Cancer (CheckMate040 Trial)
CheckMate040 Trial Summary
This trial is testing the safety and effectiveness of different doses of the immunotherapy drug nivolumab in treating hepatitis C- and B-infected patients with liver cancer, as well as patients who don't have either virus. The study is divided into two parts: first, different doses of nivolumab will be tested in each group to see if it's safe; second, the most effective dose from the first part will be given to a larger group of patients to confirm its effectiveness.
CheckMate040 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate040 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CheckMate040 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of brain issues due to liver disease.I have or had significant fluid buildup in my abdomen.I am 18 or older with advanced liver cancer not suitable for surgery or other local treatments.My liver function score is suitable for the study's requirements.I am fully active or can carry out light work.
- Group 1: HCV-infected: Nivolumab
- Group 2: HBV-infected: Nivolumab
- Group 3: Nivolumab
- Group 4: Sorafenib
- Group 5: Nivolumab plus Ipilimumab Combination
- Group 6: Child-Pugh B
- Group 7: Non-infected: Nivolumab
- Group 8: Nivolumab plus Cabozantinib Combination
- Group 9: Nivolumab plus Ipilimumab plus Cabozantinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What health conditions is Nivolumab typically administered to address?
"Nivolumab therapy is a viable option for individuals struggling with unresectable melanoma, squamous cell carcinoma, or recurrent high risk cancer."
To what extent are hospitals participating in this research endeavor?
"The medical trial consists of 14 sites, including Emory University in Atlanta, Saint Joseph's Regional Medical Center in Paterson, and CHUM in Montreal. Other locations are also available."
Are volunteers being accepted for this experiment at present?
"According to the information on clinicaltrials.gov, this trial is not seeking participants at present. Originally posted on October 30th 2012, with its most recent update occurring December 1st 2021; though it has closed recruitment, there are still 3501 other trials actively recruiting individuals for their studies."
Is there a record of any prior research conducted on Nivolumab?
"Nivolumab was first tested at Central Illinois Hematology Oncology Center in the year 2005 and 814 trials have been closed. Currently, there are 893 active experiments taking place; a considerable number of these being conducted within Atlanta, Georgia."
How many participants are being enlisted in this experiment?
"Unfortunately, this trial has ceased enrolling participants. It was posted on October 30th 2012 and the latest update occurred on December 1st 2021. If you are searching for other trials, there exist 2,608 studies recruiting patients with carcinoma and 893 actively looking for individuals taking Nivolumab."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger